Neurological disorders, depression and inflammation: Is there a common link?

Future Neurology

Volumn 10, Issue 4, 2015, Pages 327-343

  Halaris, Angelos ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; cytokines; depression; kynurenine; neuroinflammation; neurological disorders; Parkinson's disease; poststroke depression; serotonin

Indexed keywords

AMFEBUTAMONE; CELECOXIB; CHOLINESTERASE INHIBITOR; DONEPEZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; KYNURENINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; CAUSAL ATTRIBUTION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHOLINERGIC TRANSMISSION; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; INFLAMMATION; MENTAL STRESS; MOOD DISORDER; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; POSTSTROKE DEPRESSION; PRIORITY JOURNAL; REVIEW;

EID: 84939419267     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.15.18     Document Type: Review

References (112)

1. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 349(9063), 1436-1442 (1997).
2. Demyttenaere K, Bruffaerts R, Posada-Villa J et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world Mental Health surveys. JAMA 291, 2581-2590 (2004).
3. Centers for Disease Control and Prevention (CDC). Gonzalez O, Berry JT, McKnight-Eily LR et al. Current depression among adults United States, 2006 and 2008. Morb. Mortal. Wkly. Rep. 59, 1229-1235 (2010).
4. Lepin JP, Briley M. The increasing burden of depression. Neuropsych. Dis. Treat. 7 Suppl 1, 3-7 (2011).
5. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 99, 2192-2217 (1999).
6. Thielscher C, Thielscher S, Kostev K. The risk of developing depression when suffering from neurological diseases. Ger. Med. Sci. 11(Doc02). doi: 10. 3205/000170 (2013).
7. Selye H. The Story of the Adaptation Syndrome. ACTA Inc. Medical Publishers, Montreal, Canada (1952).
8. Selye H. The Stress of Life. McGraw-Hill, NY, USA (1956).
9. McEwen BS. Stress, adaptation, and disease allostasis and allostatic load. Ann. N. Y. Acad. Sci. 840(1), 33-44 (1998).
10. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 117, 289-296 (2007).
11. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol. Psychol. 74, 224-242 (2007).
12. Miller AH, Maletic V, Ralson CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry. 65, 732-741 (2009).
13. Khansari PS, Sperlagh B. Inflammation in neurological and psychiatric diseases. Inflammopharmacology 20, 103-107 (2012).
14. Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D. Neuroinflammation: the role and consequences. Neurosci. Res. 79, 1-12 (2014).
15. Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. J. Neurosci. Res. 88(8), 1615-1631 (2010).
16. Shaw PJ, McDermott MF, Kanneganti TD. Inflammasomes and autoimmunity. Trends Mol. Med. 17(2), 57-64 (2011).
17. Singhal G, Jaehne EJ, Corrigan F et al. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front. Neurosci. 8(15), 1-13 (2014).
18. Kipp M, Norkute A, Johann S et al. Brain-region-specific astroglial responses in vitro after LPS exposure. J. Mol. Neurosci. 35, 235-243 (2008).
19. Maes M, Bosmans E, Suy E et al. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiat. Scand. 84, 379-386 (1991).
20. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 11-38 (1995).
21. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 5, 375-388 (2002).
22. Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int. Immunopharmacol. 6, 1298-1304 (2006).
23. Maes M, Bosmans E, Meltzer HY et al. Interleukin-1beta: a putative mediator of HPA axis hyperactivity in major depression? Am. J. Psychiatry 150, 1189-1193 (1993).
24. Maes M, der Planken V, Van Gastel A et al. Blood coagulation and platelet aggression in major depression. J. Affect. Disord. 40, 35-40 (1996).
25. Kop WJ, Gottdiener JS, Tangen CM et al. Inflammation and coagulation factors on persons>65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am. J. Cardiol. 89, 419-424 (2002).
26. Musselman DL, Miller AH, Porter MR et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 158, 1252-1257 (2001).
27. Lindqvist D, Hall S, Surova Y et al. Cerebrospinal fluid inflammatory markers in Parkinson's disease associations with depression, fatigue, and cognitive impairment. Brain Behav. Immun. 33, 183-189 (2013).
28. Collins L, Toulouse A, Connor TJ, Nolan YM. Contributions of cental and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 62, 2154-2168 (2012).
29. Litteljohn D, Hayley S. Cytokines as potential biomarkers for Parkinson's disease: a multiplex approach. Methods Mol. Biol. 934, 121-144 (2012).
30. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62, 583-606 (1998).
31. Leonard BE. Brain cytokines and the psychopathology of depression. In: Antidepressants. Leonard BE (Ed.). Basel, Birkhauser Verlag, 109-120 (2001).
32. Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav. Immun. 16, 569-574 (2002).
33. Leonard BE, Myint A. Inflammation and depression: is there a causal connection with dementia? Neutox. Res. 10, 149-160 (2006).
34. von Knel R, Hepp U, Kraemer B et al. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J. Psychiatr. Res. 41, 744-52 (2006).
35. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol. Lett. 29, 287-291 (2008).
36. Halaris A. Inflammation, heart disease and depression. Curr. Psychiatry Rep. 15, 400 (2013).
37. Thomas AJ, Davis S, Morris C et al. Increase in interleukin-1beta in late-life depression. Am. J. Psychiatry 162, 175-177 (2005).
38. Tuglu C, Kara SH, Caliyurt O et al. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berlin) 170, 429-433 (2003).
39. Alesci S, Martinez PE, Kelkar S. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J. Clin. Endocrinol. Metab. 90, 2522-2530 (2005).
40. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferonalpha. Bihiatryol. Psyc. 56, 819-824 (2004).
41. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav. Immun. 17(Suppl. 1), S119-124 (2003).
42. Musselman DL, Lawson DH, Gumnick JF. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344, 961-966 (2001).
43. Piletz J, Halaris A, Iqbal O et al. Proinflammatory biomarkers in depression: effect of venlafaxine. World J. Biol. Psychiatry 10, 313-323 (2009).
44. Anda R, Williamson D, Jones D et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U. S. adults. Epidemiology 4, 285-294 (1993).
45. Kamphuis MH, Kalmijn S, Tijhuis MA et al. Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (FINE) study. Eur. J. Cardiovasc. Prev. Rehabil. 13, 199-206 (2006).
46. Pratt LA, Ford DE, Crum RM et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 94, 3123-3129 (1996).
47. Di Iorio A, Ferrucci L, Sparvieri E et al. Serum IL-1eta levels in health and disease: a population-based study, 'The InCHIANTI study'. Cytokine 22(6), 198-205 (2003).
48. Biasucci LM. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 110, e560-567 (2004).
49. Maes M. Introduction to the special section. Int. J. Neuropsychopharmacol. 5, 329-331 (2002).
50. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann. N. Y. Acad. Sci. 933, 222-234 (2001).
51. Vollmer-Conna U, Fazou C, Cameron B et al. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol. Med. 34, 1289-1297 (2004).
52. Smith RS. The macrophage theory of depression. Med. Hypotheses 35(4), 298-306 (1991).
53. Ur E, White PD, Grossman A. Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur. Arch. Psychiatry Clin. Neurosci. 241(5), 317-322 (1992).
54. Lett HS, Blumenthal JA, Babyak MA et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom. Med. 66, 305-315 (2004).
55. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370-379 (2000).
56. Kubera M, Lin AH, Kenis G et al. Antiinflammatory effects of antidepressants through suppression of the interferongamma/ interleukin-10 production ratio. J. Clin. Psychopharmacol. 21, 199-206 (2001).
57. Kubera M, Kenis G, Bosmans E et al. Stimulatory effect of antidepressants on the production of IL-6. Int. Immunopharmacol. 4, 185-192 (2004).
58. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 5, 401-412 (2002).
59. Himmerich H, Binder EB, Künzel HE et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol. Psychiatry 60, 882-888 (2006).
60. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum. Psychopharmacol. 25, 201-215 (2010).
61. Müller N, Schwarz MJ, Dehning S et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11, 680-684 (2006).
62. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke 36, 1330-1340 (2005).
63. Robinson RG. Post-stroke depression: prevalence, diagnosis, treatment, and disease progression. Biol. Psychiatry 54, 376-387 (2003).
64. Linden T, Blomstrand C, Skoog I. Depressive disorders after 20 months in elderly stroke patients: a case-control study. Stroke 38, 1860-1863 (2007).
65. Feng C, Min Fang M, Liu XY. The neurobiological pathogenesis of post-stroke depression. Sci. World J. 2014, doi: 10. 1155/2014/521348 (2014)
66. Kubera M, Holan V, Mathison R, Maes M. The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. Psychoneuroendocrinology 25, 785-797 (2000).
67. Lucassen PJ, Fuchs E, Czeh B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol. Psychiatry 55, 789-796 (2004).
68. Pascoe MC, Crewther SG, Carey LM, Crewther DP. Inflammation and depression: why post-stroke depression may be the norm and not the exception. Int. J. Stroke 6, 128-135 (2011).
69. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8, 382-397 (2009).
70. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 37(3), 510-518 (2010).
71. Gao HM, Jiang J, Wilson B et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81(6), 1285-1297 (2002).
72. Aizenstein HJ, Nebes RD, Saxton JA et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 1509-1517 (2008).
73. Johnston H, Boutin H, Allan SM. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem. Soc. Trans. 39, 886-890 (2011).
74. Cavanagh C, Colby-Milley J, Farso M et al. Early molecular and synaptic dysfunctions in the prodromal stages of Alzheimer's disease: focus on TNF- and IL-1?. Future Neurol. 6(6), 757-769 (2011).
75. Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol. Aging 34, 1051-1059 (2013).
76. Hollingworth P, Harold D, Jones L et al. Alzheimer's disease genetics: current knowledge and future challenges. Int. J. Geriatr. Psychiatry 26, 793-802 (2011).
77. Liu L, Chan C. The role of inflamma some in Alzheimer's disease. Ageing Res. Rev. 15, 6-15 (2014).
78. Barber R. Inflammatory signaling in Alzheimer's disease and depression. Cleve. Clin. J. Med. 78, S47-49 (2011).
79. Christmas DM, Potokar JP, Davies SJC. A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neurpsych. Dis. Treat. 7, 431-439 (2011).
80. Myint AM, Kim YK, Verkerk R et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 89(1), 143-151 (2007).
81. Myint AH, Kim YK. Cytokine-serotonin interaction through IDO; a neurodegeneration hypothesis of depression. Med. Hypotheses 61(5-6), 519-525 (2003).
82. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 1073-1074, 25-37 (2006).
83. Myint AM, Kim YK, Verkerk R et al. Tryptophan breakdown pathway in bipolar mania. J. Affect. Disord. 102(1-3), 65-72 (2007).
84. Steiner J, Walter M, Gos T et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J. Neuroinflammation 8(94) (2011).
85. Nizri E, Wirguin I, Brenner T. The role of cholinergic balance perturbation in neurological diseases. Drug News Perspect. 20(7), 421-9 (2007).
86. Brenner T, Nizri E, Irony-Tur-Sinai M et al. Acetylcholinesterase inhibitors and cholinergic modulation in myasthenia gravis and neuroinflammation. J. Neuroimmunol. 201-202, 121-127 (2008).
87. Nizri E, Brenner T. Modulation of inflammatory pathways by the immune cholinergic system. Amino Acids 45(1), 73-85 (2013).
88. Lugaresi A, Di Iorio A, Iarlori C et al. IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors. Exp. Gerontol. 39(4), 653-657 (2004).
89. Gambi F, Reale M, Iarlori C et al. Alzheimer patients treated with an AChE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. J. Clin. Psychopharmacol. 24(3), 314-321 (2004).
90. Reale M, Iarlori C, Gambi F et al. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J. Neuroimmunol. 148(1-2), 162-171 (2004).
91. Matsuwaki T, Kayasuga Y, Yamanouchi K, Nishihara M. Maintenance of gonadotropin secretion by glucocorticoids under stress conditions through the inhibition of prostaglandin synthesis in the brain. Endocrinology 147(3), 1087-1093 (2006).
92. Ma Y, Matsuwaki T, Yamanouchi K, Nishihara M. Cyclooxygenase-2-related signaling in the hypothalamus plays differential roles in response to various acute stresses. Brain Res. 1508, 23-33 (2013).
93. Cryer B, Dubois A. The advent of highly selective inhibitors of cyclooxygenase-a review. Prostaglandins Other Lipid Mediat. 56(5-6), 341-361 (1998).
94. Nery FG, Monkul ES, Hatch JP et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 23(2), 87-94 (2008).
95. Akhondzadeh S, Jafari S, Raisi F et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety 26(7), 607-611 (2009).
96. Müller N, Strassnig M, Schwarz MJ et al. COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert Opin. Investig. Drugs 13(8), 1033-1044 (2004a).
97. Müller N, Ulmschneider M, Scheppach C et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci. 254(1), 14-22 (2004b).
98. Riedel M, Strassnig M, Schwarz MJ, Muller N. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs 19(10), 805-819 (2005).
99. Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 1, 279-284 (2002).
100. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24, 395-401 (2003).
101. Miyamoto K, Miyake S, Mizuno M et al. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 129, 1984-1992 (2006).
102. Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression. JAMA 289(21), 2819-2826 (2003).
103. Esposito E, Di Matteo V, Benigno A et al. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 205(2), 295-312 (2007).
104. Vlad SC, Miler DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70, 1672-1677 (2008).
105. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63(9), 901-910 (2004).
106. Barger SW, Hörster D, Furukawa K et al. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. USA 92, 9328-9332 (1995).
107. Bruce AJ, Boling W, Kindy MS et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 2, 788-794 (1996).
108. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Med. Gen. Med. 8(2), 25 (2006).
109. Ferger B, Leng A, Mura A et al. Genetic ablation of tumor necrosis factor-alpha (TNF-) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 89, 822-833 (2004).
110. Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res. 4(4), 378-385 (2007).
111. Raison CL, Rutherford RE, Woolwine BJ et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70(1), 31-41 (2013).
112. Devaraj S, Rogers J, Jialal I. Statins and biomarkers of inflammation. Curr. Atheroscler. Rep. 9(1), 33-41 (2007).